FEATURED COMPANIES
- Almirall LLC
- Bausch Health
- Biofrontera AG
- Companies Inc.
- GlaxoSmithKline Plc.
- Leo Pharma A/S
The actinic keratosis (AK) treatment market is anticipated to grow at a CAGR of about 4.5% during the forecast period 2021-2029.
In skin care, occurrence of rough, scaly, crusty, thick patches on the skin surface showing premalignant condition is referred as actinic keratosis. Skin colour changes such as pink, brown or flesh color, hard wart type surface, rough, scaly surface, burning and it itching sensations are usually found symptoms of actinic keratosis. Usually, physical observation and skin biopsy are conducted to diagnose and confirm actinic keratosis. As per certain studies the prevalence rate of AK was about 1.95 per 10,000 people whose average was in 40s. However, this rate was about 31.81 for people with average of 80 and above.
People who are exposed to more level of sunlight, and people with fair skin have higher probability of acquiring actinic keratosis. The prevalence is higher in western countries than the Asian countries. Generally, next phase of actinic keratosis leads to squamous cell carcinoma. Squamous cell carcinoma is a kind of cancer and early treatment reduces the risk to life. Threat related with untreated actinic keratosis is 20% higher than treated actinic keratosis. Hence, it is advisable to treat early to avoid progression of actinic keratosis and eventually squamous carcinoma.
Lack of Awareness is A Key Restraining Factor
Factors such as global warming, depletion of ozone layer, increasing number of cancer cases, chronic skin diseases and problems, sedentary lifestyle are the key factors that are rising the prevalence of this is condition and therefore, the market for AK treatment. Whereas, lack of awareness related to actinic keratosis, is a major setback in the treatment of AK. Therefore, it becomes very essential to create awareness of AK and benefits of early treatment of AK so as to reduce the chances of progressing to a malignant stage.
Diagnosis Delayed Due To Pandemic
Due to COVID-19 there will be significant impact on global actinic keratosis market. Lockdowns, quarantines, social distancing, disturbed supply chain, constraints on travelling has been impacting routines and non essential services. People have been delaying visiting physicians and diagnostic centre unless it is for emergency. Similarly, healthcare institutions as filled with covid 19 patients have not been encouraging other patients to visit hospitals for non critical cases. This has significantly delayed the diagnosis and therefore, the treatment. All the more in the case of AK initial symptoms are not very severe to rush for emergency diagnosis. This has delayed the diagnosis of AK.
North America Leading the AK treatment Market
The global actinic keratosis market in this report is segmented by region as follows: North America, Europe, Asia Pacific and Rest of the World (RoW) regions. Currently, actinic keratosis market of North America is leading followed by Europe which is expected to grow comparatively at a higher rate. The reasons for growth of AK treatment market in North American and European actinic keratosis market are advanced healthcare infrastructure, awareness among people related to the disease and its treatment, high income, favourable regulatory framework and reimbursements.
Because of rapidly developing medical infrastructure, China and India are emerging markets in upcoming years. Overall, Asia Pacific region is showing significant growth over forecast period. Besides that, due to attention of Japanese government to improve the quality of healthcare facilities, Japanese market is expecting to portray boosting growth in coming years. Medical tourism will attract patients across the globe to Asia Pacific region. Increased income of people, rising literacy rate, increased spending on healthcare, demand for quality and effective treatments are the driving factors for the market growth.
Key Market Players
This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2029.
Report Scope by Segments
Market revenues and CAGR were derived from primary and secondary research. Both quantitative and qualitative trends were considered for extrapolation of market revenues. The derived market estimates were further validated from top down, bottom strategies and primary research. The scope of the market is limited to the following segments of treatment categories and region.
Key questions answered in this report
In skin care, occurrence of rough, scaly, crusty, thick patches on the skin surface showing premalignant condition is referred as actinic keratosis. Skin colour changes such as pink, brown or flesh color, hard wart type surface, rough, scaly surface, burning and it itching sensations are usually found symptoms of actinic keratosis. Usually, physical observation and skin biopsy are conducted to diagnose and confirm actinic keratosis. As per certain studies the prevalence rate of AK was about 1.95 per 10,000 people whose average was in 40s. However, this rate was about 31.81 for people with average of 80 and above.
People who are exposed to more level of sunlight, and people with fair skin have higher probability of acquiring actinic keratosis. The prevalence is higher in western countries than the Asian countries. Generally, next phase of actinic keratosis leads to squamous cell carcinoma. Squamous cell carcinoma is a kind of cancer and early treatment reduces the risk to life. Threat related with untreated actinic keratosis is 20% higher than treated actinic keratosis. Hence, it is advisable to treat early to avoid progression of actinic keratosis and eventually squamous carcinoma.
Lack of Awareness is A Key Restraining Factor
Factors such as global warming, depletion of ozone layer, increasing number of cancer cases, chronic skin diseases and problems, sedentary lifestyle are the key factors that are rising the prevalence of this is condition and therefore, the market for AK treatment. Whereas, lack of awareness related to actinic keratosis, is a major setback in the treatment of AK. Therefore, it becomes very essential to create awareness of AK and benefits of early treatment of AK so as to reduce the chances of progressing to a malignant stage.
Diagnosis Delayed Due To Pandemic
Due to COVID-19 there will be significant impact on global actinic keratosis market. Lockdowns, quarantines, social distancing, disturbed supply chain, constraints on travelling has been impacting routines and non essential services. People have been delaying visiting physicians and diagnostic centre unless it is for emergency. Similarly, healthcare institutions as filled with covid 19 patients have not been encouraging other patients to visit hospitals for non critical cases. This has significantly delayed the diagnosis and therefore, the treatment. All the more in the case of AK initial symptoms are not very severe to rush for emergency diagnosis. This has delayed the diagnosis of AK.
North America Leading the AK treatment Market
The global actinic keratosis market in this report is segmented by region as follows: North America, Europe, Asia Pacific and Rest of the World (RoW) regions. Currently, actinic keratosis market of North America is leading followed by Europe which is expected to grow comparatively at a higher rate. The reasons for growth of AK treatment market in North American and European actinic keratosis market are advanced healthcare infrastructure, awareness among people related to the disease and its treatment, high income, favourable regulatory framework and reimbursements.
Because of rapidly developing medical infrastructure, China and India are emerging markets in upcoming years. Overall, Asia Pacific region is showing significant growth over forecast period. Besides that, due to attention of Japanese government to improve the quality of healthcare facilities, Japanese market is expecting to portray boosting growth in coming years. Medical tourism will attract patients across the globe to Asia Pacific region. Increased income of people, rising literacy rate, increased spending on healthcare, demand for quality and effective treatments are the driving factors for the market growth.
Key Market Players
- Sun Pharmaceutical Industries Ltd.
- Nestle Skin Health Company
- Biofrontera AG
- Bausch Health Companies Inc.
- Novartis AG
- GlaxoSmithKline Plc.
- Leo Pharma A/S
- Almirall LLC
- Cipher Pharmaceuticals Inc.
This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2029.
Report Scope by Segments
Market revenues and CAGR were derived from primary and secondary research. Both quantitative and qualitative trends were considered for extrapolation of market revenues. The derived market estimates were further validated from top down, bottom strategies and primary research. The scope of the market is limited to the following segments of treatment categories and region.
Key questions answered in this report
- What are the key market segments in current scenario and in the future by treatment categories?
- What are the key market segments in current scenario and in the future by regions?
- What is the key impact of Covid-19 over market revenues and market determinants in the AK treatment market?
- What are the primary and secondary macro and micro factors influencing the market growth currently and during the forecast period?
- What are the primary and secondary macro and micro factors deterring the market growth currently and during the forecast period?
- How to overcome the current market challenges and leverage the opportunities in each of the market segment?
- Who are the key players in the AK treatment market and what are their key product categories and strategies?
- What are the key strategies – mergers/acquisitions/R&D/strategic partnerships etc that companies are deploying to enhance market revenues and growth?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Almirall LLC
- Bausch Health
- Biofrontera AG
- Companies Inc.
- GlaxoSmithKline Plc.
- Leo Pharma A/S
Chapter 1 Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2 Executive Summary
2.1 Global Actinic Keratosis Market Revenue, by Treatment, 2020, (US$ Million)
2.2 Global Actinic Keratosis Market Revenue, by Type of Therapy, 2020, (US$ Million)
2.3 Global Actinic Keratosis Market Revenue, by Drug Class, 2020, (US$ Million)
2.4 Global Actinic Keratosis Market Revenue, by Medication, 2020, (US$ Million)
2.5 Global Actinic Keratosis Market Revenue, by End use, 2020, (US$ Million)
2.6 Global Actinic Keratosis Market Revenue, by Geography, 2020, (US$ Million)
Chapter 3 Market Overview
3.1 Introduction and Market Definition
3.2 Disease Primer and Epidemiology
3.2 Market Lineage Analysis
3.2.1 Parent market analysis
3.2.2 Ancillary market analysis
3.3 Penetration & Growth Prospect Mapping
3.4 Product Pipeline Analysis, by Stage
3.7 Regulatory Framework
3.8 Market Dynamics
3.8.1 Drivers
3.8.1.1 High Prevalence of Actinic Keratosis and Subsequent Risk of Developing Malignancies
3.8.2 Restraints
3.8.2.1 Non-adherence to Treatments
3.8.3 Market Opportunities
3.8.3.1 Lucrative future for Light-based Treatments
3.9 Attractive Investment Proposition
3.10 Market Competition Assessment Key Players: Global Actinic Keratosis Market
Chapter 4 Actinic Keratosis Treatment Market: Segment Analysis, By Type of Therapy, 2019 - 2029 (US$ Million)
4.1 Definition and Scope
4.2 Therapy Type Market Share Analysis, 2019 & 2029
4.3 Segment Dashboard
4.4 Global Actinic Keratosis Market, by Therapy, 2019 to 2029
4.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
4.5.1 Topical
4.5.1.1 Topical market, 2019 to 2029 (US$ Million)
4.5.2 Surgery
4.5.2.1 Surgery market, 2019 to 2029 (US$ Million)
4.5.3 Photodynamic therapy
4.5.3.1 Photodynamic therapy market, 2019 to 2029 (US$ Million)
Chapter 5 Actinic Keratosis Treatment Market: Segment Analysis, By Drug Class, 2019 - 2029 (US$ Million)
5.1 Definition and Scope
5.2 Drug Class Type Market Share Analysis, 2019 & 2029
5.3 Segment Dashboard
5.4 Global Actinic Keratosis Market, by Drug Class, 2019 to 2029
5.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
5.5.1 Nucleoside metabolic inhibitors
5.5.1.1 Nucleoside metabolic inhibitors market, 2019 to 2029 (US$ Million)
5.5.2 Nonsteroidal antiinflammatory drugs
5.5.2.1 NSAIDs market, 2019 to 2029 (US$ Million)
5.5.3 Immune response modifiers
5.5.3.1 Immune response modifiers market, 2019 to 2029 (US$ Million)
5.5.4 Photoenhancers
5.5.4.1 Photoenhancers market, 2019 to 2029 (US$ Million)
5.5.5 Others
5.5.5.1 Others market, 2019 to 2029 (US$ Million)
Chapter 6 Actinic Keratosis Treatment Market: Segment Analysis, By Medication, 2019 to 2029 (US$ Million)
6.1 Definition and Scope
6.2 Medication Type Market Share Analysis, 2019 & 2029
6.3 Segment Dashboard
6.4 Global Actinic Keratosis Market, by Medication, 2019 to 2029
6.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
6.5.1 fluorouracil cream market
6.5.1.1 fluorouracil cream market, 2019 - 2029(US$ Million)
6.5.2 imiquimod
6.5.2.1 imiquimod market, 2019 - 2029(US$ Million)
6.5.3 Ingenol mebutate
6.5.3.1 Ingenol mebutate market, 2019 - 2029(US$ Million)
6.5.4 diclofenac
6.5.4.1 diclofenac market, 2019 - 2029(US$ Million)
Chapter 7 Actinic Keratosis Treatment Market: Segment Analysis, By End use, 2019 to 2029 (US$ Million)
7.1 Definition and Scope
7.2 End use Type Market Share Analysis, 2019 & 2029
7.3 Segment Dashboard
7.4 Global Actinic Keratosis Market, by End use, 2019 to 2029
7.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
7.5.1 Hospitals
7.5.1.1 Hospitals market, 2019 - 2029(US$ Million)
7.5.2 Private clinics
7.5.2.1 Private clinics market, 2019 - 2029(US$ Million)
7.5.3 Homecare
7.5.3.1 Homecare market, 2019 - 2029(US$ Million)
7.5.4 Others
7.5.4.1 Others market, 2019 - 2029(US$ Million)
Chapter 8 Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2019 & 2029
8.3 Regional Market Dashboard
8.4 Regional Market Snapshot
8.5 Regional Market Share Analysis 2019 to 2029
8.5.1 North America
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 Latin America
8.5.5 Middle East and Africa
8.6 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
8.6.1 North America
8.6.2 Europe
8.6.3 Asia Pacific
8.6.4 Latin America
8.6.5 Middle East and Africa
8.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2019 to 2029
Chapter 9 North America Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
9.1 North America market estimates and forecast, 2019-2029 (US$ Million)
9.1.1 U.S. actinic keratosis treatment market, 2019 - 2029(US$ Million)
9.1.2 Canada actinic keratosis treatment market, 2019 - 2029(US$ Million)
Chapter 10 Europe Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
10.1 Europe actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.1. U.K. actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.2. Germany actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.3. Spain actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.4. France actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.5. Italy actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.6 RoE actinic keratosis treatment market, 2019 - 2029(US$ Million)
Chapter 11 Asia Pacific Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
11.1 Asia Pacific actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.1. Japan actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.2. China actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.3. India actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.4. South Korea actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.5. Australia actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.6. RoAPAC actinic keratosis treatment market, 2019 - 2029(US$ Million)
Chapter 12 Latin America Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
12.1 Latin America actinic keratosis treatment market, 2019 - 2029(US$ Million)
12.1.1. Brazil actinic keratosis treatment market, 2019 - 2029(US$ Million)
12.1.2. Mexico actinic keratosis treatment market, 2019 - 2029(US$ Million)
12.1.3. Argentina actinic keratosis treatment market, 2019 - 2029(US$ Million)
12.1.4. RoLATAM actinic keratosis treatment market, 2019 - 2029(US$ Million
Chapter 13 Middle East and Africa Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
13.1 MEA actinic keratosis treatment market, 2019 - 2029(US$ Million)
13.1.1. Saudi Arabia actinic keratosis treatment market, 2019 - 2029(US$ Million)
13.1.2. UAE actinic keratosis treatment market, 2019 - 2029(US$ Million)
13.1.4. South Africa actinic keratosis treatment market, 2019 - 2029(US$ Million)
13.1.5. RoA actinic keratosis treatment market, 2019 - 2029(US$ Million)
Chapter 14 Actinic Keratosis Treatment Market - Competitive Analysis
14.1 Sun Pharmaceutical Industries Ltd.
14.1.1 Sun Pharmaceutical Industries Ltd.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.2 Nestle Skin Health Company
14.2.1 Nestle Skin Health Company: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.3 Biofrontera AG
14.3.1 Biofrontera AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.4 Bausch Health Companies, Inc.
14.4.1 Bausch Health Companies, Inc: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.5 Novartis AG
14.5.1 Novartis AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.6 GlaxoSmithKline Plc.
14.6.1 GlaxoSmithKline Plc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.7 Leo Pharma A/S
14.7.1 Leo Pharma A/S: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.8 Almirall LLC
14.8.1 Almirall LLC: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
14.9 Cipher Pharmaceuticals, Inc.
14.9.1 Cipher Pharmaceuticals, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
14.10 Other Notable Players
14.10.1 Other Notable Players: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2 Executive Summary
2.1 Global Actinic Keratosis Market Revenue, by Treatment, 2020, (US$ Million)
2.2 Global Actinic Keratosis Market Revenue, by Type of Therapy, 2020, (US$ Million)
2.3 Global Actinic Keratosis Market Revenue, by Drug Class, 2020, (US$ Million)
2.4 Global Actinic Keratosis Market Revenue, by Medication, 2020, (US$ Million)
2.5 Global Actinic Keratosis Market Revenue, by End use, 2020, (US$ Million)
2.6 Global Actinic Keratosis Market Revenue, by Geography, 2020, (US$ Million)
Chapter 3 Market Overview
3.1 Introduction and Market Definition
3.2 Disease Primer and Epidemiology
3.2 Market Lineage Analysis
3.2.1 Parent market analysis
3.2.2 Ancillary market analysis
3.3 Penetration & Growth Prospect Mapping
3.4 Product Pipeline Analysis, by Stage
3.7 Regulatory Framework
3.8 Market Dynamics
3.8.1 Drivers
3.8.1.1 High Prevalence of Actinic Keratosis and Subsequent Risk of Developing Malignancies
3.8.2 Restraints
3.8.2.1 Non-adherence to Treatments
3.8.3 Market Opportunities
3.8.3.1 Lucrative future for Light-based Treatments
3.9 Attractive Investment Proposition
3.10 Market Competition Assessment Key Players: Global Actinic Keratosis Market
Chapter 4 Actinic Keratosis Treatment Market: Segment Analysis, By Type of Therapy, 2019 - 2029 (US$ Million)
4.1 Definition and Scope
4.2 Therapy Type Market Share Analysis, 2019 & 2029
4.3 Segment Dashboard
4.4 Global Actinic Keratosis Market, by Therapy, 2019 to 2029
4.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
4.5.1 Topical
4.5.1.1 Topical market, 2019 to 2029 (US$ Million)
4.5.2 Surgery
4.5.2.1 Surgery market, 2019 to 2029 (US$ Million)
4.5.3 Photodynamic therapy
4.5.3.1 Photodynamic therapy market, 2019 to 2029 (US$ Million)
Chapter 5 Actinic Keratosis Treatment Market: Segment Analysis, By Drug Class, 2019 - 2029 (US$ Million)
5.1 Definition and Scope
5.2 Drug Class Type Market Share Analysis, 2019 & 2029
5.3 Segment Dashboard
5.4 Global Actinic Keratosis Market, by Drug Class, 2019 to 2029
5.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
5.5.1 Nucleoside metabolic inhibitors
5.5.1.1 Nucleoside metabolic inhibitors market, 2019 to 2029 (US$ Million)
5.5.2 Nonsteroidal antiinflammatory drugs
5.5.2.1 NSAIDs market, 2019 to 2029 (US$ Million)
5.5.3 Immune response modifiers
5.5.3.1 Immune response modifiers market, 2019 to 2029 (US$ Million)
5.5.4 Photoenhancers
5.5.4.1 Photoenhancers market, 2019 to 2029 (US$ Million)
5.5.5 Others
5.5.5.1 Others market, 2019 to 2029 (US$ Million)
Chapter 6 Actinic Keratosis Treatment Market: Segment Analysis, By Medication, 2019 to 2029 (US$ Million)
6.1 Definition and Scope
6.2 Medication Type Market Share Analysis, 2019 & 2029
6.3 Segment Dashboard
6.4 Global Actinic Keratosis Market, by Medication, 2019 to 2029
6.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
6.5.1 fluorouracil cream market
6.5.1.1 fluorouracil cream market, 2019 - 2029(US$ Million)
6.5.2 imiquimod
6.5.2.1 imiquimod market, 2019 - 2029(US$ Million)
6.5.3 Ingenol mebutate
6.5.3.1 Ingenol mebutate market, 2019 - 2029(US$ Million)
6.5.4 diclofenac
6.5.4.1 diclofenac market, 2019 - 2029(US$ Million)
Chapter 7 Actinic Keratosis Treatment Market: Segment Analysis, By End use, 2019 to 2029 (US$ Million)
7.1 Definition and Scope
7.2 End use Type Market Share Analysis, 2019 & 2029
7.3 Segment Dashboard
7.4 Global Actinic Keratosis Market, by End use, 2019 to 2029
7.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
7.5.1 Hospitals
7.5.1.1 Hospitals market, 2019 - 2029(US$ Million)
7.5.2 Private clinics
7.5.2.1 Private clinics market, 2019 - 2029(US$ Million)
7.5.3 Homecare
7.5.3.1 Homecare market, 2019 - 2029(US$ Million)
7.5.4 Others
7.5.4.1 Others market, 2019 - 2029(US$ Million)
Chapter 8 Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2019 & 2029
8.3 Regional Market Dashboard
8.4 Regional Market Snapshot
8.5 Regional Market Share Analysis 2019 to 2029
8.5.1 North America
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 Latin America
8.5.5 Middle East and Africa
8.6 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
8.6.1 North America
8.6.2 Europe
8.6.3 Asia Pacific
8.6.4 Latin America
8.6.5 Middle East and Africa
8.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2019 to 2029
Chapter 9 North America Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
9.1 North America market estimates and forecast, 2019-2029 (US$ Million)
9.1.1 U.S. actinic keratosis treatment market, 2019 - 2029(US$ Million)
9.1.2 Canada actinic keratosis treatment market, 2019 - 2029(US$ Million)
Chapter 10 Europe Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
10.1 Europe actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.1. U.K. actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.2. Germany actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.3. Spain actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.4. France actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.5. Italy actinic keratosis treatment market, 2019 - 2029(US$ Million)
10.1.6 RoE actinic keratosis treatment market, 2019 - 2029(US$ Million)
Chapter 11 Asia Pacific Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
11.1 Asia Pacific actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.1. Japan actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.2. China actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.3. India actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.4. South Korea actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.5. Australia actinic keratosis treatment market, 2019 - 2029(US$ Million)
11.1.6. RoAPAC actinic keratosis treatment market, 2019 - 2029(US$ Million)
Chapter 12 Latin America Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
12.1 Latin America actinic keratosis treatment market, 2019 - 2029(US$ Million)
12.1.1. Brazil actinic keratosis treatment market, 2019 - 2029(US$ Million)
12.1.2. Mexico actinic keratosis treatment market, 2019 - 2029(US$ Million)
12.1.3. Argentina actinic keratosis treatment market, 2019 - 2029(US$ Million)
12.1.4. RoLATAM actinic keratosis treatment market, 2019 - 2029(US$ Million
Chapter 13 Middle East and Africa Treatment Market: Regional Market Analysis, 2019 - 2029(US$ Million)
13.1 MEA actinic keratosis treatment market, 2019 - 2029(US$ Million)
13.1.1. Saudi Arabia actinic keratosis treatment market, 2019 - 2029(US$ Million)
13.1.2. UAE actinic keratosis treatment market, 2019 - 2029(US$ Million)
13.1.4. South Africa actinic keratosis treatment market, 2019 - 2029(US$ Million)
13.1.5. RoA actinic keratosis treatment market, 2019 - 2029(US$ Million)
Chapter 14 Actinic Keratosis Treatment Market - Competitive Analysis
14.1 Sun Pharmaceutical Industries Ltd.
14.1.1 Sun Pharmaceutical Industries Ltd.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.2 Nestle Skin Health Company
14.2.1 Nestle Skin Health Company: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.3 Biofrontera AG
14.3.1 Biofrontera AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.4 Bausch Health Companies, Inc.
14.4.1 Bausch Health Companies, Inc: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.5 Novartis AG
14.5.1 Novartis AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.6 GlaxoSmithKline Plc.
14.6.1 GlaxoSmithKline Plc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.7 Leo Pharma A/S
14.7.1 Leo Pharma A/S: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
14.8 Almirall LLC
14.8.1 Almirall LLC: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
14.9 Cipher Pharmaceuticals, Inc.
14.9.1 Cipher Pharmaceuticals, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
14.10 Other Notable Players
14.10.1 Other Notable Players: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
Note: Product cover images may vary from those shown
- Sun Pharmaceutical Industries Ltd.
- Nestle Skin Health Company
- Biofrontera AG
- Bausch Health
- Companies Inc.
- Novartis AG
- GlaxoSmithKline Plc.
- Leo Pharma A/S
- Almirall LLC
- Cipher Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
